BMY - BRISTOL MYERS SQUIBB CO

60.17
1.210   2.011%

Share volume: 11,516,193
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$58.96
1.21
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
71%
Profitability 73%
Dept financing 40%
Liquidity 59%
Performance 79%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.63%
1 Month
1.35%
3 Months
10.97%
6 Months
38.04%
1 Year
22.95%
2 Year
24.58%
Key data
Stock price
$60.17
P/E Ratio 
15.38
DAY RANGE
$58.54 - $60.48
EPS 
$3.47
52 WEEK RANGE
$42.52 - $62.89
52 WEEK CHANGE
$22.95
MARKET CAP 
108.526 B
YIELD 
4.65%
SHARES OUTSTANDING 
2.036 B
DIVIDEND
$0.63
EX-DIVIDEND DATE
04-02-2026
NEXT EARNINGS DATE
07-25-2025
BETA 
-0.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,100,087
AVERAGE 30 VOLUME 
$12,817,012
Company detail
CEO: Giovanni Caforio
Region: US
Website: bms.com
Employees: 34,300
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.

Recent news